Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 15;11(8):942.
doi: 10.3390/genes11080942.

Advances in Genomics for Drug Development

Roberto Spreafico  1 , Leah B Soriaga  1 , Johannes Grosse  1 , Herbert W Virgin  1 , Amalio Telenti  1
Affiliations
Review

Advances in Genomics for Drug Development

Roberto Spreafico et al. Genes (Basel). .

Abstract

Drug development (target identification, advancing drug leads to candidates for preclinical and clinical studies) can be facilitated by genetic and genomic knowledge. Here, we review the contribution of population genomics to target identification, the value of bulk and single cell gene expression analysis for understanding the biological relevance of a drug target, and genome-wide CRISPR editing for the prioritization of drug targets. In genomics, we discuss the different scope of genome-wide association studies using genotyping arrays, versus exome and whole genome sequencing. In transcriptomics, we discuss the information from drug perturbation and the selection of biomarkers. For CRISPR screens, we discuss target discovery, mechanism of action and the concept of gene to drug mapping. Harnessing genetic support increases the probability of drug developability and approval.

Keywords: CRISPR; druggability; loss-of-function.

PubMed Disclaimer

Conflict of interest statement

All authors are employees and hold stock of Vir Biotechnology Inc.

References

    1. Holbein M.E. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators. J. Investig. Med. 2009;57:688–694. doi: 10.2310/JIM.0b013e3181afdb26. - DOI - PMC - PubMed
    1. Telenti A., Pierce L.C., Biggs W.H., di Iulio J., Wong E.H., Fabani M.M., Kirkness E.F., Moustafa A., Shah N., Xie C., et al. Deep sequencing of 10,000 human genomes. Proc. Natl. Acad. Sci. USA. 2016;113:11901–11906. doi: 10.1073/pnas.1613365113. - DOI - PMC - PubMed
    1. Plenge R.M., Scolnick E.M., Altshuler D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 2013;12:581–594. doi: 10.1038/nrd4051. - DOI - PubMed
    1. Giral H., Landmesser U., Kratzer A. Into the Wild: GWAS Exploration of Non-coding RNAs. Front. Cardiovasc. Med. 2018;5:181. doi: 10.3389/fcvm.2018.00181. - DOI - PMC - PubMed
    1. King E.A., Davis J.W., Degner J.F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15:e1008489. doi: 10.1371/journal.pgen.1008489. - DOI - PMC - PubMed

LinkOut - more resources